venBio raises $528 million for its fifth fund

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got another busy day of earnings and new data readouts. Let’s get straight into it.

The need-to-know this morning

• Biotech earnings are bountiful: Moderna, Biogen, Apellis Pharmaceuticals, Neurocrine Biosciences, Ionis Pharmaceuticals, Blueprint Medicines, Agios Pharmaceuticals, Regeneron, and Alnylam Pharmaceuticals.
• Otsuka Pharmaceuticals said it is paying $800 million to acquire Jnana Therapeutics, developers of a drug for PKU.

What the 40-year quest to fight malaria teaches us about vaccine development

For decades, pharma companies and academic researchers have struggled to develop vaccines that could confer protection against malaria, fueling doubts about whether such a product was even possible. But scientists have finally succeeded — there are now two products being rolled out, one developed by GSK and partners, and the other by scientists at the University of Oxford.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In